{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:49:34Z","timestamp":1790401774496,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009052","name":"Hector Fellow Academy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009052","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BerGenBio (No grant reference number available) Hector Stiftung II"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Beyond first line, the prognosis of relapsed\/refractory (R\/R) acute myeloid leukemia (AML) patients is poor with limited treatment options. Bemcentinib is an orally bioavailable, potent, highly selective inhibitor of AXL, a receptor tyrosine kinase associated with poor prognosis, chemotherapy resistance and decreased antitumor immune response. We report bemcentinib monotherapy and bemcentinib+low-dose cytarabine combination therapy arms from the completed BerGenBio-funded open-label Phase 1\/2b trial NCT02488408 (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.clinicaltrials.gov\" ext-link-type=\"uri\">www.clinicaltrials.gov<\/jats:ext-link>\n                    ), in patients unsuitable for intensive chemotherapy. The primary objective in the monotherapy arm was identification of maximum tolerated dose with secondary objectives to identify dose-limiting toxicities, safety and efficacy, and bemcentinib pharmacokinetic profile. In the combination arm, the primary objective was safety and tolerability, with efficacy and pharmacokinetics as secondary objectives. Safety and tolerability were based on standard clinical laboratory safety tests and Common Terminology Criteria for Adverse Events version 4. Bemcentinib monotherapy (32 R\/R, 2 treatment-na\u00efve AML and 2 myelodysplasia patients) was well-tolerated and a loading\/maintenance dose of 400\/200\u2009mg was selected for combination treatment, comprising 30 R\/R and 6 treatment-na\u00efve AML patients. The most common grade 3\/4 treatment-related adverse events were cytopenia, febrile neutropenia and asymptomatic QTcF prolongation, with no grade 5 events reported. In conclusion, bemcentinib+low-dose cytarabine was safe and well tolerated.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-58179-6","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T05:03:03Z","timestamp":1742706183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b\/2a trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7650-8527","authenticated-orcid":false,"given":"Sonja","family":"Loges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-9044","authenticated-orcid":false,"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Chromik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1311-6227","authenticated-orcid":false,"given":"Grerk","family":"Sutamtewagul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Kapp-Schwoerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Crugnola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Di Renzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Lemoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesid","family":"Alvarado-Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Ben-Batalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Waizenegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa-Marie","family":"Rieckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Janning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0932-2471","authenticated-orcid":false,"given":"Maike","family":"Collienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-551X","authenticated-orcid":false,"given":"Charles D.","family":"Imbusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6538-0217","authenticated-orcid":false,"given":"Niklas","family":"Beumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2756-2591","authenticated-orcid":false,"given":"David","family":"Micklem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linn","family":"H Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00eblly","family":"Madeleine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"McCracken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Gorcea-Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn T.","family":"Gjertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,23]]},"reference":[{"key":"58179_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jfma.2022.10.007","volume":"122","author":"L-N Chien","year":"2023","unstructured":"Chien, L.-N. et al. Epidemiology and survival outcomes of acute myeloid leukemia patients in Taiwan: A national population-based analysis from 2001 to 2015. J. Formos. Med. Assoc. 122, 505\u2013513 (2023).","journal-title":"J. Formos. Med. Assoc."},{"key":"58179_CR2","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","volume":"116","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian, H. et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116, 4422\u20134429 (2010).","journal-title":"Blood"},{"key":"58179_CR3","first-page":"863","volume":"108","author":"U Krug","year":"2011","unstructured":"Krug, U., B\u00fcchner, T., Berdel, W. E. & M\u00fcller-Tidow, C. The treatment of elderly patients with acute myeloid leukemia. Dtsch. Arztebl. Int. 108, 863\u2013870 (2011).","journal-title":"Dtsch. Arztebl. Int."},{"key":"58179_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"58179_CR5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret, H. et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126, 291\u2013299 (2015).","journal-title":"Blood"},{"key":"58179_CR6","first-page":"3874","volume":"130","author":"M Dennis","year":"2017","unstructured":"Dennis, M. et al. An evaluation of 17 years of low dose cytarabine as therapy for AML patients not fit for intensive treatment, including patients with adverse cytogenetics, shows improving survival, potential underutilisation and highlights the need for new therapy. Blood 130, 3874 (2017).","journal-title":"Blood"},{"key":"58179_CR7","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S2352-3026(18)30182-0","volume":"6","author":"NJ Short","year":"2019","unstructured":"Short, N. J. et al. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 6, e29\u2013e37 (2019).","journal-title":"Lancet Haematol."},{"key":"58179_CR8","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/cncr.22496","volume":"109","author":"KA Burnett","year":"2007","unstructured":"Burnett, K. A. et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109, 1114\u20131124 (2007).","journal-title":"Cancer"},{"key":"58179_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo, C. D. et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133, 7\u201317 (2019).","journal-title":"Blood"},{"key":"58179_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617\u2013629 (2020).","journal-title":"N. Engl. J. Med."},{"key":"58179_CR11","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"A Wei","year":"2020","unstructured":"Wei, A. et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135, 2137\u20132145 (2020).","journal-title":"Blood"},{"key":"58179_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.26039","volume":"96","author":"DA Pollyea","year":"2021","unstructured":"Pollyea, D. A. et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am. J. Hematol. 96, 208\u2013217 (2021).","journal-title":"Am. J. Hematol."},{"key":"58179_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11864-015-0355-3","volume":"16","author":"SB Zeichner","year":"2015","unstructured":"Zeichner, S. B. & Arellano, M. L. Secondary adult acute myeloid leukemia: a review of our evolving understanding of a complex disease process. Curr. Treat. Options Oncol. 16, 37 (2015).","journal-title":"Curr. Treat. Options Oncol."},{"key":"58179_CR14","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3324\/haematol.2020.252569","volume":"106","author":"A Maiti","year":"2021","unstructured":"Maiti, A. et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106, 894\u2013898 (2021).","journal-title":"Haematologica"},{"key":"58179_CR15","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","volume":"2","author":"M Stahl","year":"2018","unstructured":"Stahl, M. et al. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Adv. 2, 923\u2013932 (2018).","journal-title":"Blood Adv."},{"key":"58179_CR16","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","volume":"5","author":"M Stahl","year":"2021","unstructured":"Stahl, M. et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv. 5, 1552\u20131564 (2021).","journal-title":"Blood Adv."},{"key":"58179_CR17","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/sj.leu.2401484","volume":"13","author":"C Rochlitz","year":"1999","unstructured":"Rochlitz, C. et al. Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 13, 1352\u20131358 (1999).","journal-title":"Leukemia"},{"key":"58179_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0065-230X(08)00002-X","volume":"100","author":"RMA Linger","year":"2008","unstructured":"Linger, R. M. A., Keating, A. K., Earp, H. S. & Graham, D. K. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv. Cancer Res. 100, 35\u201383 (2008).","journal-title":"Adv. Cancer Res."},{"key":"58179_CR19","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1182\/blood-2013-03-491431","volume":"122","author":"I Ben-Batalla","year":"2013","unstructured":"Ben-Batalla, I. et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood 122, 2443\u20132452 (2013).","journal-title":"Blood"},{"key":"58179_CR20","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.canlet.2008.04.017","volume":"268","author":"C-C Hong","year":"2008","unstructured":"Hong, C.-C. et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett. 268, 314\u2013324 (2008).","journal-title":"Cancer Lett."},{"key":"58179_CR21","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1038\/leu.2015.147","volume":"29","author":"I-K Park","year":"2015","unstructured":"Park, I.-K. et al. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. Leukemia 29, 2382\u20132389 (2015).","journal-title":"Leukemia"},{"key":"58179_CR22","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.3324\/haematol.2018.205385","volume":"104","author":"P-Y Dumas","year":"2019","unstructured":"Dumas, P.-Y. et al. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL. Haematologica 104, 2017\u20132027 (2019).","journal-title":"Haematologica"},{"key":"58179_CR23","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.cell.2007.10.034","volume":"131","author":"CV Rothlin","year":"2007","unstructured":"Rothlin, C. V., Ghosh, S., Zuniga, E. I., Oldstone, M. B. & Lemke, G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131, 1124\u20131136 (2007).","journal-title":"Cell"},{"key":"58179_CR24","doi-asserted-by":"publisher","first-page":"9953","DOI":"10.3390\/ijms22189953","volume":"22","author":"M Tanaka","year":"2021","unstructured":"Tanaka, M. & Siemann, D. W. Therapeutic targeting of the Gas6\/Axl signaling pathway in cancer. Int. J. Mol. Sci. 22, 9953 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"58179_CR25","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1158\/2159-8290.CD-20-1378","volume":"11","author":"I Tirado-Gonzalez","year":"2021","unstructured":"Tirado-Gonzalez, I. et al. AXL inhibition in macrophages stimulates host-versus-leukemia immunity and eradicates na\u00efve and treatment-resistant leukemia. Cancer Discov. 11, 2924\u20132943 (2021).","journal-title":"Cancer Discov."},{"key":"58179_CR26","doi-asserted-by":"publisher","first-page":"869676","DOI":"10.3389\/fimmu.2022.869676","volume":"13","author":"AST Engelsen","year":"2022","unstructured":"Engelsen, A. S. T. et al. Dissecting the role of AXL in cancer immune escape and resistance to immune checkpoint inhibition. Front. Immunol. 13, 869676 (2022).","journal-title":"Front. Immunol."},{"key":"58179_CR27","doi-asserted-by":"publisher","first-page":"100554","DOI":"10.1016\/j.xcrm.2022.100554","volume":"3","author":"H Li","year":"2022","unstructured":"Li, H. et al. AXL targeting restores PD-1 blockade sensitivity of STK11\/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells. Cell Rep. Med. 3, 100554 (2022).","journal-title":"Cell Rep. Med."},{"key":"58179_CR28","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41375-021-01452-6","volume":"36","author":"M Yang","year":"2022","unstructured":"Yang, M. et al. A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation. Leukemia 36, 675\u2013686 (2022).","journal-title":"Leukemia"},{"key":"58179_CR29","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/hmg\/9.4.645","volume":"9","author":"PM D\u2019Cruz","year":"2000","unstructured":"D\u2019Cruz, P. M. et al. Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat. Hum. Mol. Genet. 9, 645\u2013651 (2000).","journal-title":"Hum. Mol. Genet."},{"key":"58179_CR30","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1167\/iovs.02-0438","volume":"44","author":"JL Duncan","year":"2003","unstructured":"Duncan, J. L. et al. An RCS-like retinal dystrophy phenotype in mer knockout mice. Invest. Ophthalmol. Vis. Sci. 44, 826\u2013838 (2003).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"58179_CR31","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/humu.23431","volume":"39","author":"I Audo","year":"2018","unstructured":"Audo, I. et al. MERTK mutation update in inherited retinal diseases. Hum. Mutat. 39, 887\u2013913 (2018).","journal-title":"Hum. Mutat."},{"key":"58179_CR32","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/19554","volume":"398","author":"Q Lu","year":"1999","unstructured":"Lu, Q. et al. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature 398, 723\u2013728 (1999).","journal-title":"Nature"},{"key":"58179_CR33","doi-asserted-by":"publisher","first-page":"116137","DOI":"10.1016\/j.bmc.2021.116137","volume":"39","author":"S Inoue","year":"2021","unstructured":"Inoue, S. et al. Discovery of a potent and selective Axl inhibitor in preclinical model. Bioorg. Med. Chem. 39, 116137 (2021).","journal-title":"Bioorg. Med. Chem."},{"key":"58179_CR34","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.0954-6820.1920.tb18266.x","volume":"53","author":"LS Fridericia","year":"1920","unstructured":"Fridericia, L. S. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med. Scand. 53, 469\u2013486 (1920).","journal-title":"Acta Med. Scand."},{"key":"58179_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/psp4.12404","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer, R. J. NONMEM Tutorial Part I: Description of commands and options, with simple examples of population analysis. CPT Pharmacomet. Syst. Pharm. 8, 525\u2013537 (2019).","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"58179_CR36","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria (2022)."},{"key":"58179_CR37","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424\u2013447 (2017).","journal-title":"Blood"},{"key":"58179_CR38","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson, B. D., Greenberg, P. L. & Bennett, J. M. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108, 419\u2013425 (2006).","journal-title":"Blood"},{"key":"58179_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35624-4","volume":"14","author":"BS Tislevoll","year":"2023","unstructured":"Tislevoll, B. S. et al. Early response evaluation by single cell signaling profiling in acute myeloid leukemia. Nat. Commun. 14, 115 (2023).","journal-title":"Nat. Commun."},{"key":"58179_CR40","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/cyto.a.23751","volume":"95","author":"S-E Gullaksen","year":"2019","unstructured":"Gullaksen, S.-E. et al. Titrating complex mass cytometry panels. Cytom. A 95, 792\u2013796 (2019).","journal-title":"Cytom. A"},{"key":"58179_CR41","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nprot.2015.020","volume":"10","author":"ER Zunder","year":"2015","unstructured":"Zunder, E. R. et al. Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. Nat. Protoc. 10, 316\u2013333 (2015).","journal-title":"Nat. Protoc."},{"key":"58179_CR42","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/cyto.a.22826","volume":"89","author":"AH Rahman","year":"2016","unstructured":"Rahman, A. H., Tordesillas, L. & Berin, M. C. Heparin reduces nonspecific eosinophil staining artifacts in mass cytometry experiments. Cytom. A 89, 601\u2013607 (2016).","journal-title":"Cytom. A"},{"key":"58179_CR43","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/cyto.a.22625","volume":"87","author":"SV Gassen","year":"2015","unstructured":"Gassen, S. V. et al. FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. Cytom. A 87, 636\u2013645 (2015).","journal-title":"Cytom. A"},{"key":"58179_CR44","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26, 1572\u20131573 (2010).","journal-title":"Bioinformatics"},{"key":"58179_CR45","doi-asserted-by":"publisher","first-page":"e0146021","DOI":"10.1371\/journal.pone.0146021","volume":"10","author":"C Ritz","year":"2015","unstructured":"Ritz, C., Baty, F., Streibig, J. C. & Gerhard, D. Dose-response analysis using R. PLoS ONE 10, e0146021 (2015).","journal-title":"PLoS ONE"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58179-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58179-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58179-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T23:44:06Z","timestamp":1742946246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58179-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,23]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["58179"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-58179-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,23]]},"assertion":[{"value":"12 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.L. received travel support, advisory board honoraria and research funding from BerGenBio. She is currently supported by the European Research Council (ERC) under the European Union\u2019s Horizon 2020 research and innovation program (Grant Agreement No. 758713) and by the Hector Stiftung II. M.H. is a consultant, advisor and\/or speaker at AbbVie, Amgen, Bristol Myers Squibb, Certara, Glycostem, Jazz, Janssen, LabDelbert, Novartis, Pfizer, PinotBio, Servier and Sobi. His institution received research support from AbbVie, Agios, Astellas, BerGenBio, Bristol Myers Squibb, Glycostem, Jazz, Karyopharm, Loxo Oncology and PinotBio. D. Micklem, L.H.N., N. Madeleine, N. McCracken, C.O., C.G.-C. are employees at BerGenBio and may hold BerGenBio stock or stock options. The other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2846"}}